Home > Managing Your Treatment > Management Tips

Management Tips

When you are managing treatment for PI, it's important to keep track of several different factors. For people with PI who are on an Immunoglobulin (Ig) treatment, whether it is given in a vein (intravenously) or under the skin (subcutaneously),1 here are 5 things you should know about your Ig treatment:


Five Things You Should Know About Your Ig Treatment

  1. Brand: Every IV and SubQ Ig brand is made, processed, and stabilized in a different way. These differences in Ig formulations might make one brand more suitable for you than another.1 Being aware of the brand your healthcare provider has prescribed allows you to make sure it's used for each infusion. Be aware that side effects may occur more frequently in patients receiving Ig for the first time, upon switching brands or if there has been a long interval since the previous infusion. In such cases, your physician may start your infusion at a lower infusion rate and gradually increase the rate as tolerated.1
  2. Dosage: Your physician may need to adjust your dose to achieve the desired clinical response. Your dosage may also need to be adjusted, as it is based on weight and PI condition, which may vary over time.1
  3. Rate of infusion: You may find that you respond differently to different rates of infusion. Slowing down the rate of infusion can sometimes reduce side effects.2
  4. How to keep an infusion log: Tracking your response to brand, dosage, and frequency of infusion can be beneficial to both you and your treatment team. An infusion log helps you keep track of your infusions.1
  5. Where your Ig treatment comes from: It also helps to know how your Ig treatment (IV or SubQ) brand is processed. To learn more about the Shire manufacturing process and plasma collection, view About Plasma Treatment.

References: 1. Younger MEM, ed. IDF Guide for Nurses: Immunoglobulin Therapy for Primary Immunodeficiency Diseases. 4th ed. Towson, MD: Immune Deficiency Foundation; 2016. 2. Blaese RM, Bonilla FA, Stiehm ER, Younger ME, eds. Patient & Family Handbook for Primary Immunodeficiency Diseases. 5th ed. Towson, MD: Immune Deficiency Foundation; 2013.

  • MyIgSource is a patient support program for all PI patients and caregivers throughout your journey. Sign up to get access to experienced Patient and Nurse Advocates, get information about insurance and financial support, useful tools, and more.
    Learn More
  • Ask an Advocate Questions about PI or PI treatments? Our trained Patient and Nurse Advocates can help, and asking your question is easy with our Ask An Advocate feature.
    Start Getting Answers

Gammagard Liquid MyIgCoPayCard Program Terms and Conditions

This manufacturer's coupon program is not valid for prescriptions reimbursed, in whole or in part, by Medicaid, Medicare, Medigap, VA, DoD, TRICARE, or any other federal or state healthcare programs, including state pharmaceutical assistance programs, and where prohibited by the health insurance provider or by law

Shire's MyIgCoPayCard program provides a maximum total benefit of $5,000 for eligible out-of-pocket costs and expires 12 months from date of activation. Eligible costs include deductible, copayment, and co-insurance costs for eligible Shire IG (Immunoglobulin) products. Non-medication expenses, such as ancillary supplies or administration-related costs, are not eligible.

To be eligible, patients must: 1. be starting or receiving treatment with (and have current prescription for) an eligible Shire IG product with an ICD-10 for a diagnosis of Primary Immunodeficiency; and 2. have commercial insurance that covers medication costs for prescribed Shire IG product and allows for CoPay assistance; and 3. be two (2) years old or older.

Acceptance of this offer must be consistent with the terms of benefits provided by patient's health insurance provider.

Offer limited to one card per person and may not be combined with any other coupon, discount, prescription savings card, rebate, free trial, patient assistance, or other offer.

This program is only valid for residents of the United States.

Shire reserves the right to change or discontinue this program at any time without notice.

This is not health insurance.


Add to patient instructions:

If your insurance situation changes, it is your responsibility to notify MyIgSource's CoPay assistance program.

© 2017 Shire. All rights reserved.

SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates. Gammagard Liquid is a trademark or registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.

S30515 04/17

Please expand for Indication and Important Safety Information.


What is the most important information that I should know about GAMMAGARD LIQUID?

GAMMAGARD LIQUID can cause the following serious reactions: severe allergic reactions causing difficulty in breathing or skin rashes; decreased kidney function or kidney failure; blood clots in the heart, brain, lungs or elsewhere in the body; severe headache, drowsiness, fever, painful eye movements, or nausea and vomiting; dark colored urine, swelling, fatigue, or difficulty breathing.